MedPath

Extended Retroperitoneal Lymphadenectomy and Nerve Plexus Clearance Versus Standard Lymphadenectomy in Pancreaticoduodenectomy

Not Applicable
Conditions
Pancreaticoduodenectomy
Interventions
Procedure: standard lymphadenectomy
Procedure: extended lymphadenectomy and nerve clearance
Registration Number
NCT03081351
Lead Sponsor
Shanghai Zhongshan Hospital
Brief Summary

This clinical trial is about the survival benefit of extended lymphadenectomy and nerve clearance versus standard lymphadenectomy in pancreaticoduodenectomy of pancreatic adenocarcinoma,which is a multicenter,prospective,ramdomized clinical trials.

Detailed Description

The purpose of this clinical trial is for assessing the survival benefit of extended lymphadenectomy and nerve clearance versus standard lymphadenectomy in pancreaticoduodenectomy of pancreatic adenocarcinoma. And we will focus on the R0 resection using LEEPP(Leeds Pathology Protocol) methods to check whether the tumor is eradicated or not.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
480
Inclusion Criteria
  • 18-70 years; Karnofsky performance>70; preoperative diagnosis as resectable pancreatic head cancer; patients' relative have signed consent form.
Exclusion Criteria
  • also have severe cardiopulmonary disease, autoimmune disease, chronic renal failure disease; recurrent pancreatic tumor or unresectable tumor; benign pancreatic tumor; also have other malignant tumors.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
standard lymphadenectomystandard lymphadenectomyThe investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
extended lymphadenectomy and nerve clearanceextended lymphadenectomy and nerve clearanceThe investigators will implement the pancreaticoduodenectomy using the principle of "Total Peripancreas Excision" to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node.
Primary Outcome Measures
NameTimeMethod
Overall survivalFrom date of randomization until the date of death from any cause, assessed up to 100 months

The overall survival of the patients from the time of surgery until the date of pass-away.

Secondary Outcome Measures
NameTimeMethod
Disease free survivalFrom date of randomization until the date of first documented progression( local recurrence or metastasis), assessed up to 100 months.

The time of the surgery until the date of the local recurrence or metastasis.

Trial Locations

Locations (1)

Zhongshan Hospital, Fudan University

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath